1
Arctic sea ice reaches another low in 2026
Arctic sea ice is shrinking in both summer and winter, and what remains is getting younger and thinner, according to nearly five decades of satellite observations. NASA and the National Snow and Ice Data Center reported that this year's September minimum was among the lowest in the record. Summer losses have slowed over the past decade, partly because increased cloud cover has reduced sunlight reaching the ice, NASA researchers said. Multiyear ice, which survives summer melt and is thicker, has declined significantly, leaving more thin first-year ice vulnerable to melting. Natural cycles such as the Arctic Oscillation shape conditions from year to year, but scientists say they cannot fully explain the loss, which they tie to rising global temperatures.
Key facts
- Scientists project the Arctic Ocean could be essentially ice-free in summer at least once before mid-century.
- The smallest September sea ice extent ever observed occurred in September 2012.
- Every summer from 2007 through 2026 ranks among the 20 lowest September extents on record.
- March 2026 maximum statistically tied March 2025 for the lowest winter peak in the satellite record.
- The September 12, 2026 minimum covered about 4.6 million square kilometers, tying for 10th-lowest since monitoring began.
Commentary
Sources: Science Daily
2
Two statues of Ramesses II up to 8.5 meters tall discovered in Egypt
Fragments of two large royal statues were unearthed in Egypt after a resident found a stone mass with inscriptions on their property and alerted the authorities. Experts identified one head, about 1.6 meters tall and wearing the double crown of Upper and Lower Egypt, as a depiction of Ramses II, and estimated the complete statue, including its base, at roughly 8.5 meters, though only fragments have been recovered. A second statue, with a preserved section of nearly 2.5 meters, is still being investigated to determine whether it also shows Ramses II. Inscriptions on a nearby piece of pink granite call the ruler King of Upper and Lower Egypt and son of Ra. Archaeologists are still working to establish whether the statues stood at the site originally or were moved there later.
Key facts
- Excavation followed a resident finding a stone mass with inscriptions on their property in Egypt
- One statue head, about 1.6 meters tall, has been identified as Ramses II
- Estimated full height of the Ramses II statue, including base, is about 8.5 meters
- A second statue's preserved section is nearly 2.5 meters high and is still being investigated
- Ramses II reigned from 1279 to 1213 BC
Commentary
Sources: Unboxholics
3
Brain implants are helping people who have lost their voice speak
Casey Harrell, a climate activist who has amyotrophic lateral sclerosis (ALS), can communicate again through an experimental brain-computer interface that decodes his speech directly from his neural activity. Harrell said losing his voice was the most important thing the disease took from him. Researchers at UC Davis say the work suggests speech could be restored for people with ALS, stroke, paralysis, cerebral palsy and Parkinson's disease. Harrell's system is still bulky, slow and wired, and he can use it only at home. Paradromics, a neurotechnology company, is testing a portable implant, with safety assessed first before the goal of real-time speech. Experts say costs, invasive surgery and possible changes to the brain over time remain unresolved.
Key facts
- Harrell has used a UC Davis brain-computer interface since four electrode devices were implanted in 2023.
- Harrell uses his system for 10 to 14 hours daily, according to the researchers working with him.
- A Nature Medicine report in June said Harrell had communicated nearly 2 million words.
- An estimated 35,000 people in the United States are affected by ALS.
- Paradromics' dime-sized implant, holding 421 electrodes, was placed in a 68-year-old woman's brain in June.
Commentary
Sources: Science News
4
Stroke Rates Among Younger Adults Rose Sharply Between 1993 and 2020
Strokes are becoming more common among younger adults, challenging the long-held view that they mainly affect older people, according to a study published in Neurology on September 23, 2026. Researchers examined cases in Greater Cincinnati and Northern Kentucky from 1993 to 2020 and found the rate of first strokes in this group rose sharply. Blocked blood vessels, known as ischemic strokes, accounted for most of the increase, while bleeding strokes did not rise. Risk factors including high blood pressure, diabetes, atrial fibrillation and substance use also became more common, but the researchers could not determine how much they contributed. Survival improved over the period, though survivors may face lasting complications, and the researchers said more research is needed to explain the trend.
Key facts
- Stroke rate among adults aged 20 to 54 rose from 33.9 to 62.2 per 100,000 person-years between 1993-1994 and 2020.
- Ischemic stroke rate among younger adults rose from 23.8 to 47.3 per 100,000 person-years over the period.
- Substance use among younger stroke patients rose from 4.6% in 1993-1994 to 40.2% in 2020, mostly linked to marijuana.
- Thirty-day deaths after stroke fell from 11.7% to 9.4%, after adjusting for age, race and sex.
Commentary
Sources: Science Daily
5
Ozempic and Wegovy linked to rare risk of sudden vision loss
A large study led by Rutgers researchers, published in Annals of Internal Medicine, links GLP-1 drugs such as Ozempic and Wegovy to a slightly higher risk of ischemic optic neuropathy, a rare condition that can cause sudden, potentially permanent vision loss. The analysis covered US adults aged 18 to 65 with Type 2 diabetes who had recently started treatment. Chintan Dave said the increase was small but clinically important. Cases were more common among men and adults aged 50 to 65. Dave said about one-third of affected patients recover some vision, usually within six months. The researchers caution that the findings do not prove the drugs directly damage the optic nerve, since other differences in patients' health could explain the increase.
Key facts
- Ischemic optic neuropathy occurs when blood flow to the optic nerve is reduced.
- GLP-1 medications studied include semaglutide and tirzepatide, sold as Mounjaro and Zepbound.
- Dave said the excess risk was about three to four additional cases per 10,000 patients over 18 months.
- More than 80% of cases involve the non-arteritic anterior form of the condition.
- The condition usually affects part of the vision in one eye rather than causing complete blindness.
Commentary
Sources: Science Daily